Poster 27
- Kelley Tangredi
- May 23, 2024
- 1 min read
Updated: Jun 27, 2024
Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD)
Authors: Stephan Weidinger; Andrew Blauvelt; Kim Papp; Adam Reich; Chih-Hung Lee; Margitta Worm; Charles Lynde; Yoko Kataoka; Peter Foley; Christine Weber; Anne-Catherine Solente; Samuel Adelman; Sonya Davey; Wanling Wong; Natalie Rynkiewicz; Karl Yen; John T. O’Malley; Charlotte Bernigaud
Poster 27